Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check28 days agoChange DetectedA sitewide NIH announcement about a transition from “Artificial Intelligence” to “Super Intelligence” terminology appears above the study record.SummaryDifference0.4%

- Check35 days agoChange DetectedThe footer now identifies the site as running revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check62 days agoChange DetectedA new revision entry v3.7.0 was added to the history and the previous v3.6.6 entry was removed, reflecting an underlying site update rather than changes to the study data.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page footer revision was updated from v3.6.5 to v3.6.6, indicating a minor update to the page rendering.SummaryDifference0.1%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.